Session 07: Metabolic status and risk of disease Ketosis in dairy cows: Prevention and therapy

S. Dänicke

Abstract:Introduction Ketosis in dairy cows is characterized by increased levels of circulating ketone bodies, particularly of beta-hydroxybutyrate (BHB), as a result of the inability of the liver to metabolize an excess of non-esterified fatty acids (NEFA) which is typically observed shortly after calving. In this period the energy intake of the cow increases more slowly than the milk energy output does ultimately resulting in a negative energy balance (NEB) and a stimulated lipolysis. Thus, the p.p. lipomobilization syndrome is accompanied by hyperketonaemia and hepatolipidosis (e.g. [1]). Based on the absence or presence of clinical symptoms in combination with the levels of BHB in blood circulation the hyperketonaemia is classified as either subclinical or clinical ketosis irrespective of pathogenesis. Most authors define a subclinical ketosis at BHB concentrations between ≥1.2 and ≤2.0 mMol/L although these thresholds should be considered a convention (e.g. [2-4]). Clinical signs are often paralleled by BHB concentrations of >2.0 mMol/L although they might be absent even at higher BHB levels. Considering this classification it becomes clear that a medical treatment is mostly confined to clinical cases while subclinical cases usually are not discovered and consequently not treated. Preventive measures need to be implemented in view of the significant incidence of subclinical ketosis, its adverse impact on dry matter intake and milk yield, and its association with clinical ketosis and other productions diseases, such as displaced abomasum, metritis and mastitis [2] but also with vaccination success ([5]). Based on the fact that a subclinical ketosis is at high risk to derail into a clinical ketosis prevention of the subclinical form concurrently reduces the incidence of clinical cases and should be the method of choice.

Medicine,Agricultural and Food Sciences